Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tamtuvetmab (AT-005), a caninised version of blontuvetmab targeting CD52, enhances progression-free survival (PFS) and demonstrates in vivo efficacy for treating naïve T-cell lymphoma (LSA) in dogs. The compound has received veterinary approval [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Tamtuvetmab (AT-005), a caninised version of blontuvetmab targeting CD52, enhances progression-free survival (PFS) and demonstrates in vivo efficacy for treating naïve T-cell lymphoma (LSA) in dogs. The compound has received veterinary approval [1] [2]. |
In vivo | Tamtuvetmab, administered intravenously at a concentration of 5 mg/mL and volumes ranging from 7.5 to 30 mL over 15 to 30 minutes, demonstrates in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). However, it is associated with adverse effects including vomiting, weight loss, diarrhea, lethargy, reduced appetite, and anorexia [1]. |
Synonyms | AT-005, AT005 |
Molecular Weight | N/A |
CAS No. | 1608122-71-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tamtuvetmab 1608122-71-9 AT-005 AT005 inhibitor inhibit